

ANNOUNCEMENT

The Board of Directors of Malaysian Genomics Resource Centre Berhad (hereinafter referred to as "MGRC" or "the Company") and its subsidiaries ("the Group") hereby announce the following unaudited results for the fourth quarter ended 30 June 2012.

A PRESENTATION OF RESULTS
I CONDENSED STATEMENT OF COMPREHENSIVE INCOME

for the financial period ended	4th Quarter		Year-to-Date	
	Current Year	Previous Year	Current Year	Previous Year
	30.6.2012 (RM'000)	30.6.2011 (RM'000)	30.6.2012 (RM'000)	30.6.2011 (RM'000)
Revenue	1,068	4,766	9,843	12,146
Interest income from fixed deposits	86	155	485	531
Marketing and distribution	(111)	(150)	(614)	(628)
Employee benefits and expense	(821)	(968)	(4,147)	(3,197)
Depreciation and amortisation	(510)	(376)	(1,911)	(1,032)
Lab consumables	(194)	(1,074)	(2,162)	(1,140)
Research collaboration costs	(40)	-	(1,040)	-
Exclusive license fee	(63)	(62)	(249)	(250)
System maintenance cost	(301)	(301)	(1,204)	(1,204)
Administrative expenses	(695)	(638)	(2,540)	(2,448)
Foreign exchange gain / (loss)	-	34	(5)	-
Profit / (loss) from operations	(1,581)	1,386	(3,544)	2,778
Finance costs	-	-	-	-
Profit / (loss) before tax	(1,581)	1,386	(3,544)	2,778
Income tax expenses	(22)	(39)	(116)	(142)
Profit / (loss), net of tax, representing total comprehensive income	(1,603)	1,347	(3,660)	2,636
Profit / (loss) attributable to:				
Shareholders of the Company	(1,603)	1,347	(3,660)	2,636
Minority interest	-	-	-	-
Net profit / (loss) for the period	(1,603)	1,347	(3,660)	2,636
Earnings / (Loss) per share (EPS) attributable to the equity holders of the Company (sen)				
Basic EPS	(1.70)	1.43	(3.89)	2.93
Diluted EPS	N/A	N/A	N/A	N/A

The unaudited condensed statement of comprehensive income should be read in conjunction with the audited financial statements for the year ended 30 June 2011 and the accompanying explanatory notes that form an integral part of the Interim Financial Statements.

Note:-

There is no income/expense in relation to other income including investment income, provision for/write-off of receivables, provision for/write-off of inventories, gain/loss on disposal of quoted or unquoted investments or properties, impairment of assets, gain/loss on derivatives, or exceptional items.

A PRESENTATION OF RESULTS (cont.)
II CONDENSED STATEMENT OF FINANCIAL POSITION

as at	30.6.2012 (RM'000)	30.6.2011 (RM'000)
ASSETS		
NON-CURRENT ASSETS		
Plant and equipment	5,653	5,356
Intangible asset	4,226	4,837
CURRENT ASSETS		
Trade and other receivables	6,888	3,020
Inventories	785	623
Other current assets	956	1,427
Cash and bank balances	12,110	22,369
TOTAL ASSETS	30,618	37,632
EQUITY AND LIABILITIES		
EQUITY ATTRIBUTABLE TO OWNERS OF THE PARENT		
Share capital	9,410	9,410
Share premium	14,755	14,755
Retained earnings	4,852	8,512
TOTAL EQUITY	29,017	32,677
CURRENT LIABILITIES		
Trade and other payables	1,573	4,903
Tax payable	28	52
TOTAL LIABILITIES	1,601	4,955
TOTAL EQUITY AND LIABILITIES	30,618	37,632
Net assets (RM'000)	29,017	32,677
Net assets per share attributable to equity holders of the Company (sen)	30.84	34.73

The unaudited condensed statement of financial position should be read in conjunction with the audited financial statements for the year ended 30 June 2011 and the accompanying explanatory notes that form an integral part of the Interim Financial Statements.

A PRESENTATION OF RESULTS (cont.)
III CONDENSED STATEMENT OF CHANGES IN EQUITY

	Equity, Total (RM'000)	← Non-Distributable →		Distributable Retained Earnings (RM'000)
		Share Capital (RM'000)	Share Premium (RM'000)	
for the financial year ended 30 June 2011				
Opening balance at 1 July 2010	14,751	7,700	1,175	5,876
Total comprehensive income / (loss)	2,636	-	-	2,636
Transaction with owners				
Issuance of new shares	18,468	1,710	16,758	-
Share issuance expense	(3,178)	-	(3,178)	-
Total transaction with owners	15,290	1,710	13,580	-
Closing balance at 30 June 2011	32,677	9,410	14,755	8,512
for the financial year ended 30 June 2012				
Opening balance at 1 July 2011	32,677	9,410	14,755	8,512
Total comprehensive income / (loss)	(3,660)	-	-	(3,660)
Closing balance at 30 June 2012	29,017	9,410	14,755	4,852

The unaudited condensed statement of changes in equity should be read in conjunction with the audited financial statements for the year ended 30 June 2011 and the accompanying explanatory notes that form an integral part of the Interim Financial Statements.

A PRESENTATION OF RESULTS (cont.)
IV CONDENSED STATEMENT OF CASH FLOWS

for the financial period ended	Year-to-Date	
	Current Year	Previous Year
	30.6.2012	30.6.2011
	(RM'000)	(RM'000)
Cash flows from operating activities		
Profit / (loss) before tax	(3,544)	2,777
Adjustments for:		
Amortisation of intangible assets	611	611
Depreciation of plant and equipment	1,300	421
Interest income	(485)	(531)
Operating profit / (loss) before working capital changes	(2,118)	3,278
(Increase) / decrease in receivables	(3,397)	(1,233)
(Increase) / decrease in inventories	(162)	(623)
(Decrease) / increase in payables	(3,630)	676
Cash (used in) / generated from operations	(9,307)	2,098
Taxes paid	(140)	(90)
Net cash (used in) / generated from operating activities	(9,447)	2,008
Cash flows from investing activities		
Interest received	485	531
Purchase of plant and equipment	(1,297)	(5,097)
Net cash (used in) / generated from investing activities	(812)	(4,566)
Cash flows from financing activities		
Proceeds from issuance of shares	-	18,468
Share issuance expenses	-	(3,178)
Net cash generated from / (used in) financing activities	-	15,290
Net (decrease) / increase in cash and cash equivalents	(10,259)	12,732
Cash and cash equivalents at beginning of the period	22,369	9,637
Cash and cash equivalents at end of period	12,110	22,369

The unaudited condensed statement of cash flows should be read in conjunction with the audited financial statements for the year ended 30 June 2011 and the accompanying explanatory notes that form an integral part of the Interim Financial Statements.

UNAUDITED NOTES TO THE INTERIM FINANCIAL STATEMENTS**B Explanatory Notes Pursuant to FRS 134****i Basis of Preparation & Changes in Accounting Policies**

The interim financial statements are unaudited and have been prepared in accordance with FRS 134 Interim Financial Reporting and Paragraph 9.22 and Appendix 9B of the Bursa ACE Market Listing Requirements.

This report should be read in conjunction with the audited financial statements for the year ended 30 June 2011 and the accompanying explanatory notes. The explanatory notes provide an explanation of events and transactions that are significant for an understanding of the changes in the financial position and performance of the Group and Company since the year ended 30 June 2011.

Statement on changes in accounting policies arising from the adoption of new/revised Financial Reporting Standards ("FRS")

The significant accounting policies and methods of computation adopted for these interim financial statements are consistent with those adopted for the audited financial statement for the financial year ended 30 June 2011 except for the adoption of new and revised FRSs, Amendments to FRSs and Interpretations as listed in the audited financial statements for the financial year ended 30 June 2011 which were effective for the financial periods beginning on or after 1 January 2011.

The adoption of the new FRSs, Amendments to FRSs and Interpretations have no significant impact on the financial statements of the Group and Company other than for the application of FRS 7, which will entail the additional disclosures in the 2012 annual financial statements.

ii Auditors' Report on Preceding Annual Financial Statements

The audited financial statements for the year ended 30 June 2011 were not qualified.

iii Seasonal and Cyclical Factors

The operations of MGRC were not significantly affected by seasonal and cyclical factors.

iv Material and Unusual Items Affecting Assets, Liabilities, Equity, Net Income or Cash Flow

There were no material and unusual items affecting assets, liabilities, equity, net income or cash flows during the financial period.

v Material Changes in Estimates

There were no material changes in the estimates that had effect(s) on the financial period.

vi Debt and Equity Securities

There were no issues, repurchases and repayments of debt and equity securities for the financial period to date.

vii Dividends Paid

There were no dividends paid for the financial period.

viii Segmental Information

FRS 8 requires identification of reporting segment on the basis of internal reports that are regularly reviewed by the entity's Chief Operating Decision Maker in order to allocate resources to the segment and assess its performance. The management monitors the operating results of the Group as a whole for the purpose of making decisions about resource allocation and performance assessment. Accordingly, the Group has only one reportable segment for the period under review as well as the foreseeable future. Please refer to the financial statements presented in Part A of this announcement.

B Explanatory Notes Pursuant to FRS 134 (cont.)

ix Valuation of Plant and Equipment

There has been no valuation made on any of the Group's plant and equipment during the current financial period under review.

x Subsequent Events

There were no material events subsequent to the end of the current financial period under review that have not been reflected, except for:-

- a) The 50:50 joint venture company of MGRC and Ajmaks Sdn. Bhd. ("AJMAKS"), MPath Sdn Bhd ("MPath" or "the Buyer"), had on 19 July 2012 agreed to the terms and entered into a conditional sale and purchase agreement for shares ("Shares SPA"), for the acquisitions of:-
- i) up to 2,100,000 ordinary shares of RM1.00 each representing 70% of the total issued and paid-up share capital of Clinipath (Malaysia) Sdn Bhd ("CM") for a cash consideration not exceeding the sum of RM13,140,000 together with the amount of any long outstanding debts of CM recovered after the completion date;
 - ii) 90,000 ordinary shares of RM1.00 each representing 100% of the total issued and paid-up share capital of Clinipath Capital Sdn Bhd ("CC") for a cash consideration of RM150,000; and
 - iii) 2 ordinary shares of RM1.00 each representing 100% of the total issued and paid-up share capital of Medical Scan Sdn Bhd ("MS") for a cash consideration of RM10,000.
- (CM, CC and MS are collectively known as the "Clinipath Group") ("Proposed Acquisitions of Clinipath Group").
- b) Further, one of the conditions precedent of the Shares SPA under part (a) above is the entry into by the Buyer, of a conditional sale and purchase agreement to acquire property at a later date ("Property SPA") for a cash consideration of RM2,300,000 ("Proposed Acquisition of Property").

xi Changes in the Composition of the Group

There were no changes in the composition of the Group, including business combinations, acquisition or disposal of subsidiaries and long-term investments, restructuring and discontinuing operations for the financial period to date, other than the following:-

- a) On 25 April 2012, MGRC subscribed one (1) ordinary share of RM1.00 each, representing 50% equity interest in MGRC International Sdn. Bhd. ("MGRCI") for a cash consideration of RM1.00. Subsequently, MGRC had also on the same day, acquired the remaining one (1) subscriber's share, representing 50% equity interest in MGRCI for a cash consideration of RM1.00. As a consequence thereto, MGRCI became a wholly-owned subsidiary of MGRC.
- b) On 11 May 2012, acquired one (1) ordinary share of RM1.00, representing 50% equity interest in MPath for a cash consideration of RM1.00.

xii Contingent Liabilities or Contingent Assets

There was no contingent liability or contingent asset arising since the last audited annual balance sheet date as at 30 June 2011.

xiii Capital Commitments

There were no material capital commitments for the purchase of property, plant and equipment that were not provided for in the interim financial statements as at the end of the financial period.

B Explanatory Notes Pursuant to FRS 134 (cont.)
xiv Related Party Transactions

Save as disclosed below, there were no significant related party transactions during the financial period to date:-

a) Significant Related Party Transactions

for the financial period ended Related Party		Nature of Transaction	4th Quarter		Year-to-Date	
			Current Year	Previous Year	Current Year	Previous Year
			30.6.2012 (RM'000)	30.6.2011 (RM'000)	30.6.2012 (RM'000)	30.6.2011 (RM'000)
Neuramatix, our ultimate holding company.	Management fee payable to Neuramatix pursuant to Shared Services Agreement.	220	224	943	798	
Synamatix, our holding company.	Exclusive licence fees payable to Synamatix with respect of software developed by Synamatix pursuant to Software License Agreement.	63	62	249	250	
Synamatix, our holding company.	System maintenance fees payable to Synamatix for annual maintenance of software licensed by MGRC pursuant to Software License Agreement.	301	301	1,204	1,204	
		584	587	2,396	2,252	

b) Compensation of Key Management Personnel (excluding directors)

	4th Quarter		Year-to-Date	
	Current Year	Previous Year	Current Year	Previous Year
	30.6.2012 (RM'000)	30.6.2011 (RM'000)	30.6.2012 (RM'000)	30.6.2011 (RM'000)
Salaries, allowances and bonuses	443	356	1,524	984
Contributions to defined contribution plan	16	16	66	58
Social security contributions	-	-	1	-
Estimated money value of benefits-in-kind	-	-	-	56
Total short-term employee benefits	459	372	1,591	1,098

xv Cash and Cash Equivalents

as at	Current Year	Previous Year
	30.6.2012 (RM'000)	30.6.2011 (RM'000)
Cash on hand and at banks	180	69
Deposits with licensed banks	11,930	22,300
	12,110	22,369

xvi Inventories

There was no write-down of inventories during the financial period to date.

C Explanatory Notes Pursuant to Appendix 9B, ACE Market Listing Requirements
i Performance of the Group
Current Year 4th Quarter versus Previous Year 4th Quarter

For the fourth quarter ended 30 June 2012, the Group recorded a revenue of RM1.1 million, which represents a reduction of RM3.7 million as compared to a revenue of RM4.8 million for the fourth quarter in the preceding year.

For the current quarter, the Group recorded a loss before taxation of RM1.6 million as compared to a profit before taxation of RM1.4 million in the same quarter of the preceding year.

The loss before taxation was mainly due to lower revenue (RM1.1 million versus RM4.8 million). Accordingly, there is a reduction in lab consumables associated with the MOSTI Projects (RM0.2 million versus RM1.1 million).

Current Year-to-Date versus Previous Year-to-Date

The Group recorded a revenue of RM9.8 million, which represents a reduction of RM2.3 million as compared to a revenue of RM12.1 million in the previous year-to-date. We continue to see revenue from smaller projects and the decrease was mainly due to the successful completion of our projects with BiotechCorp and the Ministry of Science, Technology and Innovation ("MOSTI").

The Group registered a loss before taxation of RM3.5 million as compared to a profit before taxation of RM2.8 million in the corresponding period of the previous year. This was mainly due to decrease in revenue (RM9.8 million versus RM12.1 million), increased costs for lab consumables (RM2.2 million versus RM1.1 million), research collaboration costs of RM1.0 million as well as the hiring of key research and development personnel (RM4.1 million versus RM3.2 million). Higher depreciation and amortisation expenses (RM1.9 million versus RM1.0 million) were incurred, corresponding to an increase in plant and equipment (RM9.5 million versus RM7.9 million) for our genetic screening services.

ii Comparison with Preceding Quarter's Results

The comparison of this quarter's results with the preceding quarter is set out below.

	Current Quarter	Preceding Quarter	Variance
for the financial period ended	30.6.2012	31.3.2012	
	(RM'000)	(RM'000)	(RM'000)
Revenue	1,068	2,330	(1,262)
Profit / (loss) before tax	(1,581)	(1,055)	(526)

The variance in revenue can be attributed to a deferment of interim milestones for the MOSTI projects. As a result, there was a corresponding decrease in expenditure on lab consumables (RM0.2 million versus RM0.7 million). The Group also incurred lower employee benefits expense of RM0.4 million.

iii Prospects of the Group

MGRC has developed genetic screening products aimed at hospitals, specialist medical centres and consumer market segments under the brand Dtect. Other than releasing products for the screening of non-communicable diseases, new products in the pipeline will also screen for an array of communicable and infectious diseases. The release of more products will be rolled out on a progressive basis.

Once the purchase of Clinipath Group has been completed by MPath, this will represent an established network of around 800 primary care clinics and 8 hospitals/specialist medical centres for the Dtect products serving all major cities in Peninsular and East Malaysia.

In addition, the Group will continue to explore investment opportunities in related businesses both in Malaysia and overseas via its recently announced entities, MGRCI and MPath.

C Explanatory Notes Pursuant to Appendix 9B, ACE Market Listing Requirements (cont.)
iv Variance from Profit Forecast

The Group did not publish any profit forecast.

v Taxation

MGRC's BioNexus pioneer status accords the Company with tax exemption on its statutory income for qualifying activities. The Group's effective tax rate for the current financial year is thus lower than the Malaysian statutory tax rate of 25%.

Taxation for the financial period ended	4th Quarter		Year-to-Date	
	Current Year 30.6.2012 (RM'000)	Previous Year 30.6.2011 (RM'000)	Current Year 30.6.2012 (RM'000)	Previous Year 30.6.2011 (RM'000)
Malaysian income tax:				
Current period	27	39	121	142
Prior period	(5)	-	(5)	-
Total	22	39	116	142

The above tax has arisen in relation to interest income.

vi Status of Corporate Proposal

There is no corporate proposal announced but not completed as at the date of this announcement.

vii Status of Utilisation of Proceeds from Issue of Shares

The Company was listed on the ACE Market of Bursa on 5 October 2010 ("Date of Listing"). The Company raised RM18.5 million from its Initial Public Offering ("IPO") and the details of utilisation of such proceeds as at 30 June 2012 are as follows:

Utilisation of Proceeds Purpose Details (if available)	Initial Timeframe for Utilisation	Proposed Utilisation (RM'000)	Actual Utilisation (RM'000)	Balance of Amount Allocated		Explanation
				(RM'000)	(%)	
Capital expenditure	Within two (2) years from the Date of Listing	6,000	5,704	296	5%	
Laboratory equipment		900	850	50	6%	
Computer hardware & software						
R&D expenditure	Within two (2) years from the Date of Listing	1,510	687	823	55%	
Marketing expenditure	Within three (3) years from the Date of Listing	2,000	1,077	923	46%	
Working capital	Within two (2) years from the Date of Listing	4,568	4,880	(312)	-7%	#
Listing expenses	Within one (1) month from the Date of Listing	3,490	3,178	312	9%	#
Total utilisation of funds		18,468	16,376	2,092	11%	

The under utilisation of listing expenses is adjusted to working capital.

C Explanatory Notes Pursuant to Appendix 9B, ACE Market Listing Requirements (cont.)
viii Borrowings

The Group does not have any borrowings as at 30 June 2012.

ix Material Litigations

As at the date of this announcement, there are no material litigations against the Group or taken by the Group.

x Dividends

No dividends were declared during the current financial year under review.

xi EPS

- a) **Basic EPS** Computed by dividing the profit / (loss), net of tax, attributable to owners of the parent for the financial period by the weighted average of the number of ordinary shares in issue during the period.

Basic EPS for the financial period ended	4th Quarter		Year-to-Date	
	Current Year 30.6.2012	Previous Year 30.6.2011	Current Year 30.6.2012	Previous Year 30.6.2011
Profit / (loss), net of tax, attributable to owners of the parent (RM'000)	(1,603)	1,347	(3,660)	2,636
Weighted average number of ordinary shares of RM0.10 each in issue ('000)	94,100	94,100	94,100	89,825
Basic EPS (sen)	(1.70)	1.43	(3.89)	2.93

- b) **Diluted EPS** The Group does not have any convertible shares or convertible financial instruments for the current financial quarter and financial period to date.

xii Disclosure of Realised and Unrealised Profits / (Losses)

as at	30.6.2012 (RM'000)	31.3.2012 (RM'000)
Realised	4,852	6,455
Unrealised	-	-
Retained profit / (loss)	4,852	6,455

xiii Authorisation for Issue

The interim financial statements were authorised for issue by the Board of Directors in accordance with a Resolution of the Directors dated 27 August 2012.